MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Outlook Arena
- Jan 27, 2004 - GSK Consumer: Reverses topline trend but…
GSK Consumer: Reverses topline trend but…
GlaxoSmithKline Consumer Healthcare (erstwhile SmithKline Beecham Consumer Healthcare) has reported nearly 8% growth in net sales (value terms) and 4.8% (volume terms) during the December quarter. However, weakness in the operating margins continued and the company finished the quarter with over 35% dip in profit before tax. However, owing to a deferred tax credit, which the company got the benefit of, GSK Consumer finished December quarter with over 83% net profit growth.
| (Rs m) | 4QFY03 | 4QFY04 | Change | FY03 | FY03 | Change |
| Net sales | 1,782 | 1,917 | 7.6% | 7,525 | 7,991 | 6.2% |
| Other Income | 40 | 46 | 14.3% | 146 | 194 | 32.8% |
| Expenditure | 1,516 | 1,753 | 15.6% | 6,026 | 6,836 | 13.4% |
| Operating Profit (EBDIT) | 266 | 165 | -38.1% | 1,498 | 1,155 | -22.9% |
| Operating Profit Margin (%) | 14.9% | 8.6% | 19.9% | 14.5% | ||
| Interest (net) | 8 | -9 | - | 24 | -4 | - |
| Depreciation | 96 | 89 | -7.6% | 257 | 358 | 39.1% |
| Profit before Tax | 202 | 130 | -35.4% | 1,364 | 996 | -27.0% |
| Tax | 69 | -64 | - | 453 | 232 | -48.7% |
| Extraordinary items | -26 | 0 | - | -61 | 0 | - |
| Profit after Tax/(Loss) | 106 | 194 | 83.6% | 850 | 764 | -10.2% |
| Net profit margin (%) | 5.9% | 10.1% | 11.3% | 9.6% | ||
| No. of Shares (eoy) (m) | 45.4 | 45.4 | 45.4 | 45.4 | ||
| Diluted Earnings per share* | 9.3 | 17.1 | 18.7 | 16.8 | ||
| *(annualised) | ||||||
| Current P/e ratio | 17.2 | 17.5 |
OUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
GSK CONSUMER SHARE PRICE
Apr 15, 2020 (Close)
TRACK GSK CONSUMER
- Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK CONSUMER
GSK CONSUMER 8-QTR ANALYSIS
COMPARE GSK CONSUMER WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.